Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...

Ryan Gusto earned the last opening-day spot in the Astros' bullpen. How he got there is a testament to taking advantage of an ...

Twelve years ago, a group of Down syndrome families celebrated with pizza at Mr. G's. Now the celebration turned into nearly ...

FDA Breakthrough Therapy Designation granted to lacutamab for relapsed or refractory Sézary syndrome New data, including lacutamab improved health-related quality of life data from TELLOMAK ...

Katie Lowe is pictured with the display she set up for “World Down Syndrome Day 2025 at the Warwick Public Library. Katie, ...